

We claim:

1. An isolated and purified polypeptide which is a fragment of SEQ ID NO:32, wherein said polypeptide has a molecular weight of about 90 kDa and comprises the amino acid sequence of SEQ ID NO:61.
- 5 2. The polypeptide of claim 1, wherein the polypeptide has the sequence of SEQ ID NO:48.
3. An isolated and purified polypeptide which is a fragment of SEQ ID NO:32, wherein said polypeptide has a molecular weight of about 35 kDa and comprises the amino acid sequence of SEQ ID NO:61.
- 10 4. The polypeptide of claim 3, wherein the polypeptide has the sequence of SEQ ID NO:49.
5. An isolated and purified polypeptide which is a fragment of SEQ ID NO:28, wherein said polypeptide has a molecular weight of about 35 kDa and comprises the amino acid sequence of SEQ ID NO:61.
- 15 6. The polypeptide of claim 3, wherein the polypeptide has the sequence of SEQ ID NO:53.
7. A peptide of about 10 amino acids comprising SEQ ID NO:61.
8. The peptide of claim 7 wherein the peptide sequence is selected from the group consisting of SEQ ID NO:50, SEQ ID NO:51 and SEQ ID NO:52.
- 20 9. A method for inhibiting metastatic tumor formation in an individual comprising the step of administering to the individual a peptide of about 10 amino acids comprising SEQ ID NO:61.
10. The peptide of claim 9 wherein the peptide sequence is selected from the group consisting of SEQ ID NO:50, SEQ ID NO:51 and SEQ ID NO:52.
- 25 11. The peptide of claim 9 wherein the peptide sequence is SEQ ID NO:50.

12. The peptide of claim 9 wherein the peptide sequence is SEQ ID NO:51.
  13. The peptide of claim 9 wherein the peptide sequence is SEQ ID NO:52.
  14. The method of claim 9 wherein the metastatic tumor is a lung tumor.
  15. The method of claim 9, wherein the peptide is administered in combination with
- 5 a pharmaceutically acceptable excipient.